Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management

12 november 2026 bijgewerkt door: The Collagen Co. - GLP-1 Users

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.

Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

40

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Adults aged 18-55 years at the time of enrollment.
  • Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
  • Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
  • Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
  • Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
  • In good general health.
  • Resides in the United States.

Exclusion Criteria:

  • Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
  • Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
  • Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
  • Currently testing, or plan to in the next 12 weeks, a product for another research study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Glow Shakes Premium Collagen Meal Replacement Arm

Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Perceived Nutritional Adequacy
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire

Baseline to Week 12

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Body Fat Percentage
Tijdsspanne: Baseline to Week 12

Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Muscle Mass
Tijdsspanne: Baseline to Week 12

Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Self-Reported Weight Management and Food Cravings
Tijdsspanne: Baseline to Week 12

Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Perceived Skin Smoothness
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived skin smoothness score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Perceived Skin Elasticity
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived skin elasticity score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hunger Intensity
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Satiety Duration
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Food Craving Scores
Tijdsspanne: Baseline to Week 12

Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Hair Thickness
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived hair thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hair Health
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived hair health assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Energy Levels
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived energy levels assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Cognitive Focus
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived cognitive focus assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Thickness
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived nail thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Health
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived nail health assessed via self-report questionnaire

Baseline to Week 12
Change in Gut Comfort and Digestive Health
Tijdsspanne: Baseline to Week 12

Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Metabolism Support
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived metabolism support assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Physical Strength
Tijdsspanne: Baseline to Week 12

Within-participant change in perceived physical strength assessed via self-report questionnaire

Baseline to Week 12
Product Tolerability and Participant Satisfaction
Tijdsspanne: Week 12

Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire

Week 12

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 januari 2027

Studie voltooiing (Geschat)

1 januari 2027

Studieregistratiedata

Eerst ingediend

12 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren